Related Experiment Videos
Vaccine strategies against Pseudomonas aeruginosa infection in the lung
A W Cripps1, M L Dunkley, R L Clancy
1Faculty of Applied Science, University of Canberra, Australia.
Abstract:
Pseudomonas aeruginosa is an environmentally ubiquitous, extracellular opportunistic gram-negative bacteria that causes significant morbidity and mortality to a disproportionately high degree for infections with this bacteria compared with other gram-negative bacteria. Patients at particular risk of infection are those with compromised respiratory function, in intensive-care support and taking immunocompromising pharmaceutical agents. Once acquired, infection is difficult to eradicate with chemotherapy and attempts to vaccinate against infection have been of little success. Over the past five years, we have pursued the concept of mucosal immunisation against respiratory infection with P. aeruginosa. Initial studies in an acute animal model clearly demonstrated that mucosal immunisation with a killed whole bacterial cell preparation could induce protective immune responses in the lung. Subsequent studies have shown that the protective immune mechanisms were dependent on antigen specific CD4+ T cells, the activation of alveolar macrophages, the recruitment and activation of polymorphs, predominantly neutrophils, the controlled secretion of TNF-alpha, IL-1 and IFN gamma and the presence of antibody. We have hypothesised that the protective response is under the control of T cells. A pre-clinical human trial of an oral whole killed cell preparation has been completed with no adverse side effects. A limited open trial in patients with bronchiectasis has also been completed. Preliminary analysis of the results has demonstrated that after oral vaccination, specific lymphocyte responses were observed to P. aeruginosa.
Insights
Mucosal immunization with killed Pseudomonas aeruginosa bacteria can protect against respiratory infections. This approach, involving oral vaccination, stimulates immune responses in patients, offering a potential new strategy against this difficult-to-treat pathogen.
Area of Science:
- Immunology
- Microbiology
- Infectious Diseases
Background:
- Pseudomonas aeruginosa is a gram-negative bacterium causing severe respiratory infections, particularly in vulnerable patients.
- Current treatments are often ineffective, and vaccine development has faced challenges.
- There is a need for novel strategies to prevent and treat P. aeruginosa infections.
Purpose of the Study:
- To investigate the efficacy of mucosal immunization against Pseudomonas aeruginosa respiratory infections.
- To elucidate the immune mechanisms underlying protection induced by mucosal vaccination.
- To assess the safety and immunogenicity of an oral killed whole cell P. aeruginosa vaccine in humans.
Main Methods:
- Studies in animal models demonstrated protective immune responses in the lungs after mucosal immunization.
- Investigated the role of CD4+ T cells, alveolar macrophages, neutrophils, cytokines (TNF-alpha, IL-1, IFN-gamma), and antibodies in protective immunity.
- Conducted pre-clinical human trials and a limited open trial in patients with bronchiectasis using an oral killed whole cell preparation.
Main Results:
- Mucosal immunization with killed P. aeruginosa induced protective immune responses in the lung in animal models.
- Protective mechanisms involved T cells, macrophages, neutrophils, specific cytokines, and antibodies.
- An oral killed whole cell preparation was safe in pre-clinical human trials.
- A trial in bronchiectasis patients showed specific lymphocyte responses to P. aeruginosa after oral vaccination.
Conclusions:
- Mucosal immunization is a promising strategy for preventing P. aeruginosa respiratory infections.
- The protective immune response is T cell-dependent and involves a coordinated cellular and humoral immunity.
- Oral vaccination with killed P. aeruginosa is safe and immunogenic in humans, warranting further investigation.